ProShares UltraPro S&P500 vs GeneDx Holdings Corp — how do they compare? ProShares UltraPro S&P500 trades at $154.9, while GeneDx Holdings Corp trades at $81.95 (market cap $2.44B). The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| UPRO | WGS | |
|---|---|---|
Sector | Leveraged / Inverse | Technology |
52-Week High | $155.10 | $167.51 |
52-Week Low | $89.29 | $34.51 |
Market Cap | — | $2.44B |
Enterprise Value | — | $2.48B |
Signals from Pluang's Aura AI — not financial advice
UPRO trades at $154.38, down 0.39% on the day, while maintaining a bullish technical outlook with strong moving average signals. The leveraged ETF tracking the S&P 500 faces mixed sentiment as oscillators show neutral readings amid record market highs. Recent institutional activity includes Bay Colony Advisors establishing a new position, indicating professional interest despite valuation concerns in the broader market.
The ETF's performance remains tied to S&P 500 momentum, with technical strength supporting near-term upside potential. However, elevated RSI levels and market-wide valuation concerns present headwinds. The absence of traditional fundamental metrics for this leveraged product emphasizes its tactical rather than long-term investment nature.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Trailing returns across standard periods
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →